Suprachoroidal drug delivery is an ocular route of drug administration. It involves using a microneedle to provide a minimally invasive method and injecting particles of a medication into the suprachoroidal space (SCS) between the sclera and choroid in the eye. Suprachoroidal drug delivery is a non-traditional approach for administering medication to the eye, leveraging a microneedle-based technique to achieve a minimally invasive method of injection. This process introduces drug particles directly into the suprachoroidal space (SCS), which is located between the sclera and the choroid. Unlike traditional ocular delivery routes, suprachoroidal administration offers several advantages, including reduced invasiveness and a lower risk of complications such as traumatic cataracts or retinal tears. By targeting the SCS, this method allows drugs to bypass the various natural barriers of the eye—namely the blood-aqueous, outer blood-retinal, and inner blood-retinal barriers—that can limit the efficacy and penetration of therapeutic agents. This ability to navigate around these protective barriers significantly enhances the effectiveness of the drug, providing more direct and efficient delivery to the desired ocular tissues. Microneedles, which are central to this delivery technique, can be utilized in different areas of the eye, but targeting the SCS is particularly critical. The SCS plays a key role in maintaining intraocular pressure, making it a prime location for therapeutic intervention. Microneedle devices can be precisely engineered and customized to meet specific therapeutic needs, offering a high degree of flexibility and control. Notably, microneedle-based drug delivery has been shown to increase the amount of drug delivered to the eye by up to 60 times when compared to traditional topical applications. Their ability to deliver drugs efficiently into the eye makes them a compelling choice for non-invasive treatment options, and ongoing developments continue to refine their application in ocular therapies. Diseases like macular degeneration (AMD), diabetic retinopathy, and glaucoma all have the potential to be alleviated by using microneedle delivery.
Suprachoroidal space The suprachoroidal space (SCS) is a potential anatomical space situated between the sclera and the choroid, typically collapsed under normal physiological conditions due to intraocular pressure (IOP) and the presence of collagenous fibers that anchor the sclera to the choroid. Despite its collapsed state, the SCS plays an important physiological role in maintaining intraocular pressure and supporting fluid drainage through pathways such as the uveoscleral outflow. In recent years, the SCS has gained attention as a strategic site for ocular drug delivery, especially for targeting diseases of the posterior segment of the eye, including age-related macular degeneration, diabetic retinopathy, and uveitis. Because the SCS lies adjacent to the highly vascular choroid and near the retina, it offers direct access to posterior ocular tissues, making it an ideal route for localized treatment. Therapeutics administered into the SCS can be delivered more precisely, often requiring lower doses than traditional routes such as intravitreal or systemic administration, while achieving equivalent or enhanced therapeutic effects. Furthermore, drugs remain compartmentalized within the SCS, reducing exposure to non-target tissues in the anterior segment of the eye. This localized containment minimizes the risk of side effects, such as cataract formation or increased IOP, which are more commonly associated with conventional therapies. Additionally, the SCS can be accessed using minimally invasive microneedle technology, allowing for repeatable and controlled administration with reduced patient discomfort and fewer complications compared to subretinal surgery. As a result, the SCS is emerging not only as a valuable target for delivering small molecules, corticosteroids, and gene therapies but also as a potential biomarker for disease activity, particularly in conditions involving inflammation or choroidal congestion. With continued advancements in imaging and injection techniques, the suprachoroidal space holds promise for transforming the landscape of posterior segment ocular therapies.
Traditional routes of ocular drug delivery Drug delivery to the suprachoroidal space can be achieved through a variety of advanced techniques, each offering distinct advantages and challenges. One of the most commonly used methods involves topical applications, such as eye drops. While convenient, this approach suffers from limited efficiency in drug delivery, particularly when compared to more sophisticated techniques like microcatheters, nanoparticles, and microneedles. Microcatheters, for instance, provide the ability to precisely target and directly visualize the delivery of therapeutic agents into the SCS. However, this method is not without its drawbacks, as it carries certain risks and demands a high level of expertise from the operator. The delicate nature of the procedure and the potential for complications make it a less favorable option for some patients. Research into nanoparticle-based drug delivery is actively underway, with several studies in the early stages of exploration. Nanoparticles hold significant promise due to their ability to enhance the stability and bioavailability of drugs, as well as their potential for more efficient and targeted delivery. While the field is still in its infancy, the growing body of research offers future prospects for the future of ocular therapy.
Types of microneedles used in ocular drug delivery
… excerpt ends here. Continue reading the full article.
